In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma.
Health Professionals
Melanoma tumors thicker than 0.8 mm increase risk for death
The crude incidence rate of melanoma-related death 20 years after diagnosis was 6% for those with tumors thinner than 0.8 mm.
Nivolumab/Ipilimumab Continues to Show Survival Benefit in Melanoma
The CheckMate 067 trial found that, at a 10-year follow-up, nivolumab/ipilimumab elicited a median OS of 71.9 months in patients with previously untreated, advanced melanoma.
Tumor Upstaging in Invasive Melanoma Linked to Worse Survival Outcomes
Shortfalls in clinical management may explain why tumor upstaging in invasive melanoma is associated with worse survival outcomes, according to study findings published in the Journal of the American Academy of Dermatology.